Comparative Pharmacology
Head-to-head clinical analysis: QOLIANA versus SUFENTANIL CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QOLIANA versus SUFENTANIL CITRATE.
QOLIANA vs SUFENTANIL CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Selective mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
0.5-5 mcg/kg IV/IM for induction of anesthesia; 0.1-0.3 mcg/kg IV for epidural analgesia; 0.3-0.8 mcg/kg IV for short operative procedures; maintenance with 0.1-0.3 mcg/kg IV every 1-2 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Terminal elimination half-life: 2-4 hours (adults), 1-3 hours (neonates), 3-6 hours (elderly). Context: context-sensitive half-time increases with infusion duration.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Renal (metabolites, <1% unchanged); fecal (biliary elimination of metabolites); approximately 80% renal, 20% fecal.
Category C
Category D/X
Opioid Agonist
Opioid Agonist